

3rd Global summit on

ONCOLOGY AND CANCER

May 06-07, 2019 Tokyo, Japan

Improving the viability of Pseudo-islets for efficient insulin production research area anti-tumor

Mohammadali Soleimani Damaneh

University of Chinese Academy of Sciences, Beijing

Recently, many efforts have been made to find new BRD4 inhibitors, that is why we have to understand and develop a New Anti-Cancer Agents (NACAs) for BRD4 inhibition, then we have been working in this area for several years and newly we figured out some results and finally, a new BRD4 inhibitor Hjp-b-171 was derived from one PLK1-BRD4 dual inhibitor BI-2536. The most important is that Hjp-b-171 has potential anti-tumor activity and it selectively blocks the BET. Actually, the anti-tumor effect of Hjp-b-171 compound was effective approvingly as much better than positive control (+)-JQ-1 and OTX-015, according to results including both *in vitro* and *in vivo* antitumor experiments. In conclusion, this research showed that a new BRD4 inhibitor, Hjp-b-171, is more effective in inhibiting cell proliferation and potently down-regulates several common oncogenes, including c-MYC. metabolism and pharmacokinetics data identified Hjp-b-171 has the potential to become one candidate drug as a BRD4 inhibitor.

2016b8012307005@simm.ac.cn

Notes: